Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases
| العنوان: | Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases |
|---|---|
| المؤلفون: | Faivre, Coline, Villani, Axel Patrice, Aubin, François, Lipsker, Dan, Bottaro, Martine, Cohen, Jean-David, Durupt, François, Jeudy, Géraldine, Sbidian, Émilie, Toussirot, Eric, Badot, Valérie, Barbarot, Sébastien, Debarbieux, Sebastien, Delaporte, Emmanuel, Goegebeur, Guetty, Morel, Jacques, Nassif, Aude, Duru, Gérard, Jullien, Denis, Club Rheumatisms and Inflammation, French Society of Dermatology and |
| المساهمون: | Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Strasbourg, Centre hospitalier de Valence, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Loire Vendée Océan, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Département de Pédiatrie et maladies infectieuses [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Centre Médical de l'Institut Pasteur, Institut Pasteur [Paris], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Médical de l'Institut Pasteur (CMIP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP) |
| المصدر: | Journal of The American Academy of Dermatology Journal of The American Academy of Dermatology, Elsevier, 2016, 74 (6), pp.1153-1159. ⟨10.1016/j.jaad.2016.01.018⟩ Journal of The American Academy of Dermatology, 2016, 74 (6), pp.1153-1159. ⟨10.1016/j.jaad.2016.01.018⟩ |
| بيانات النشر: | HAL CCSD, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, biologic agents, Dermatology, Antibodies, Monoclonal, Humanized, tumor necrosis factor-alfa inhibitors, Etanercept, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Crohn Disease, Recurrence, Psoriasis, Adalimumab, Medicine, Humans, Hidradenitis suppurativa, Adverse effect, Retrospective Studies, 030203 arthritis & rheumatology, Biological Products, business.industry, Drug Substitution, Arthritis, Anti-Inflammatory Agents, Non-Steroidal, hidradenitis suppurativa, Paradoxical reaction, Middle Aged, medicine.disease, Infliximab, 3. Good health, Discontinuation, Surgery, Withholding Treatment, Female, paradoxical reactions, Drug Eruptions, business, Rituximab, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug |
| الوصف: | International audience; BACKGROUND:Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported.OBJECTIVE:We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA.METHODS:This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA.RESULTS:We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients.LIMITATIONS:Retrospective nature and lack of complete follow-up for some patients are limitations.CONCLUSION:HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched. |
| اللغة: | English |
| تدمد: | 0190-9622 1097-6787 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee7da285c95c9d9ec642a05ac1dec26dTest https://hal.archives-ouvertes.fr/hal-01873018Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....ee7da285c95c9d9ec642a05ac1dec26d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 01909622 10976787 |
|---|